These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 36826057)

  • 1. Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone.
    Santos da Silva E; Servais JY; Kohnen M; Arendt V; Gilson G; Staub T; Seguin-Devaux C; Perez-Bercoff D
    Curr Issues Mol Biol; 2023 Feb; 45(2):1741-1761. PubMed ID: 36826057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
    Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
    Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
    Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
    Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 vaccination of convalescents boosts neutralization capacity against Omicron subvariants BA.1, BA.2 and BA.5 and can be predicted by anti-S antibody concentrations in serological assays.
    Seidel A; Hoffmann S; Jahrsdörfer B; Körper S; Ludwig C; Vieweg C; Albers D; von Maltitz P; Müller R; Lotfi R; Wuchter P; Klüter H; Kirchhoff F; Schmidt M; Münch J; Schrezenmeier H
    Front Immunol; 2023; 14():1170759. PubMed ID: 37180152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant neutralizing escapes of Omicron and its sublineages in SARS-CoV-2-infected individuals vaccinated with inactivated vaccines.
    Shen F; Yang CX; Lu Y; Zhang M; Tian RR; Dong XQ; Li AQ; Zheng YT; Pang W
    J Med Virol; 2023 Feb; 95(2):e28516. PubMed ID: 36680413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U
    Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
    Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
    Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.
    Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Couto CIC; Güler A; Mampilli V; Schmitt GJ; Mottl J; Ziegenhals T; Fesser S; Reinholz J; Wernig F; Schraut KG; Hefesha H; Cai H; Yang Q; Walzer KC; Grosser J; Strauss S; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Kohmer N; Ciesek S; Swanson KA; Vogel AB; Türeci Ö; Sahin U
    Sci Immunol; 2022 Dec; 7(78):eade9888. PubMed ID: 36378074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron.
    Amano M; Otsu S; Uemura Y; Ichikawa Y; Matsumoto S; Higashi-Kuwata N; Matsushita S; Shimada S; Mitsuya H
    Sci Rep; 2023 Oct; 13(1):17404. PubMed ID: 37833390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
    Planas D; Staropoli I; Porot F; Guivel-Benhassine F; Handala L; Prot M; Bolland WH; Puech J; Péré H; Veyer D; Sève A; Simon-Lorière E; Bruel T; Prazuck T; Stefic K; Hocqueloux L; Schwartz O
    Med; 2022 Dec; 3(12):838-847.e3. PubMed ID: 36228619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.
    Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY
    Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine.
    Xie X; Zou J; Kurhade C; Liu M; Ren P; Pei-Yong Shi
    Cell Rep; 2022 Nov; 41(9):111729. PubMed ID: 36402138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong.
    Zhou R; Liu N; Li X; Peng Q; Yiu CK; Huang H; Yang D; Du Z; Kwok HY; Au KK; Cai JP; Fan-Ngai Hung I; Kai-Wang To K; Xu X; Yuen KY; Chen Z
    Lancet Reg Health West Pac; 2023 Mar; 32():100660. PubMed ID: 36591327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies against Omicron BA.5 among children with infection alone, vaccination alone, and hybrid immunity.
    Suntronwong N; Kanokudom S; Assawakosri S; Vichaiwattana P; Klinfueng S; Phowatthanasathian H; Chansaenroj J; Srimuan D; Thatsanathorn T; Duangchinda T; Chantima W; Pakchotanon P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    Int J Infect Dis; 2023 Sep; 134():18-22. PubMed ID: 37207716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.